Page last updated: 2024-11-10

thiambutosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiambutosine: thiourea antileprotic agent used in patients who cannot tolerate sulfones; minor descriptor (77-85); on-line & Index Medicus PHENYLTHIOUREA/AA (77-85) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3002003
CHEMBL ID2107052
SCHEMBL ID1961184
MeSH IDM0262995

Synonyms (50)

Synonym
unii-x92j960c7p
4-13-00-01179 (beilstein handbook reference)
x92j960c7p ,
thiambutosinum
tiambutosina
{[4-(dimethylamino)phenyl]amino}[(4-butoxyphenyl)amino]methane-1-thione
1-(4-butoxyphenyl)-3-(4-dimethylaminophenyl)thiourea
thiourea, n-(4-butoxyphenyl)-n'-(4-(dimethylamino)phenyl)-
nsc 682
tiambutosina [inn-spanish]
einecs 207-914-0
thiambutosine [inn:ban]
brn 2819159
4-butoxy-4'-(dimethylamino)thiocarbanilide
1-(p-butoxyphenyl)-3-(p-dimethylaminophenyl)-2-thiourea
thiambutosinum [inn-latin]
thiambutosine
thiambutosin
carbanilide, 4-butoxy-4'-(dimethylamino)thio-
summit 1906
su 1906
500-89-0
nsc-682
nsc682
thiourea, n-(4-butoxyphenyl)-n'-[4-(dimethylamino)phenyl]-
ciba 1906
ciba-1906
CHEMBL2107052
thiambutosine [inn]
thiambutosine [mart.]
SCHEMBL1961184
JYCBKPOKWDDOOV-UHFFFAOYSA-N
thaimbutosine
n-(4-butoxyphenyl)-n'-[4-(dimethylamino)phenyl]thiourea #
DTXSID20198175
n-(4-butoxyphenyl)-n'-[4-(dimethylamino)phenyl]thiourea
1-(4-butoxyphenyl)-3-(4-(dimethylamino)phenyl)thiourea
ZB0038
Q15725413
BCP30136
1-(4-butoxyphenyl)-3-[4-(dimethylamino)phenyl]thiourea
D93488
AS-56443
AKOS037645047
bdbm50269301
sc 682
su1906
sc682
su-1906
sc-682
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)0.37000.00102.030810.0000AID1487664
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1487663Inhibition of human mPGES-1 expressed in 293-F cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 30 secs at 10 uM by enzyme immunoassay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Selective inhibitors of human mPGES-1 from structure-based computational screening.
AID1487664Inhibition of human mPGES-1 expressed in 293-F cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 30 secs enzyme immunoassay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Selective inhibitors of human mPGES-1 from structure-based computational screening.
AID1487665Inhibition of ovine COX1/human COX2 assessed as reduction in PGH2 production by measuring PGF2alpha at 100 uM using PG-acetylcholinesterase as tracer by colorimetry2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Selective inhibitors of human mPGES-1 from structure-based computational screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (89.47)18.7374
1990's1 (5.26)18.2507
2000's0 (0.00)29.6817
2010's1 (5.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.52 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]